Table 2. Multiple analysis: evaluation of prognostic factors for DFS.
| HR | 95% CI | P-value | |
|---|---|---|---|
| Age | 1.134 | 1.011–1.273 | 0.0325 |
| Sex | 1.331 | 1.036–1.711 | 0.0255 |
| Tumour size | 1.432 | 1.119–1.831 | 0.0043 |
| Number of metastatic lymph nodes | 1.369 | 1.058–1.771 | 0.0169 |
| Histopathological grading | 1.241 | 0.950–1.621 | 0.1132 |
| Location of tumour | 0.8169 | ||
| Left colon and sigmoid | 1.095 | 0.814–1.472 | |
| Flexures and transverse colon | 1.097 | 0.766–1.571 | |
| Treatment with LEV | 1.430 | 1.115–1.835 | 0.0049 |
| Treatment with IFN | 0.942 | 0.736–1.206 | 0.6364 |
For the HR, the reference category for categorical covariates was female for sex, ⩽3 metastatic lymph nodes for number of metastatic lymph nodes, G1/G2 for histopathological grading, caecum and right colon for location of tumour, no LEV for treatment with LEV and no IFN for treatment with IFN. DFS=disease-free survival; LEV=levamisole; IFN=interferon alfa.